Scott D. Taylor

Scott D. Taylor

Auto-generated profile, based on publicly available information

Scott D. Taylor

Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
ZTZhixin Cyrillus Tan
Zhixin Cyrillus Tan
MMMadeleine C Murphy
Madeleine C Murphy
HAHakan S Alpay
Hakan S Alpay
STScott D Taylor
Scott D Taylor
AMAaron S Meyer
Aaron S Meyer
Systems serology provides a broad view of humoral immunity by profiling both the antigen‐binding and Fc properties of antibodies. These studies contain structured biophysical profiling across disease‐relevant antigen targets, alongside additional measurements made for single antigens or in an antigen‐generic manner. Identifying patterns in these measurements helps guide vaccine and therapeutic antibody development, improve our understanding of diseases, and discover conserved regulatory mechanisms. Here, we report that coupled matrix–tensor factorization (CMTF) can reduce these data into consistent patterns by recognizing the intrinsic structure of these data. We use measurements from two previous studies of HIV‐ and SARS‐CoV‐2‐infected subjects as examples. CMTF outperforms standard methods like principal components analysis in the extent of data reduction while maintaining equivalent prediction of immune functional responses and disease status. Under CMTF, model interpretation improves through effective data reduction, separation of the Fc and antigen‐binding effects, and recognition of consistent patterns across individual measurements. Data reduction also helps make prediction models more replicable. Therefore, we propose that CMTF is an effective general strategy for data exploration in systems serology.

17 October 2023 in Science Signaling
Verified
Journal Article
Closed access
BOBrian T. Orcutt-Jahns
Brian T. Orcutt-Jahns
PEPeter C. Emmel
Peter C. Emmel
ESEli M. Snyder
Eli M. Snyder
STScott D. Taylor
Scott D. Taylor
AMAaron S. Meyer
Aaron S. Meyer
The cytokine interleukin-2 (IL-2) has the potential to treat autoimmune disease but is limited by its modest specificity toward immunosuppressive regulatory T (T reg ) cells. IL-2 receptors consist of combinations of α, β, and γ chains of variable affinity and cell specificity. Engineering IL-2 to treat autoimmunity has primarily focused on retaining binding to the relatively T reg -selective, high-affinity receptor while reducing binding to the less selective, low-affinity receptor. However, we found that refining the designs to focus on targeting the high-affinity receptor through avidity effects is key to optimizing T reg selectivity. We profiled the dynamics and dose dependency of signaling responses in primary human immune cells induced by engineered fusions composed of either wild-type IL-2 or mutant forms with altered affinity, valency, and fusion to the antibody Fc region for stability. T reg selectivity and signaling response variations were explained by a model of multivalent binding and dimer-enhanced avidity—a combined measure of the strength, number, and conformation of interaction sites—from which we designed tetravalent IL-2–Fc fusions that had greater T reg selectivity in culture than do current designs. Biasing avidity toward IL2Rα with an asymmetrical multivalent design consisting of one α/β chain–binding and one α chain–binding mutant further enhanced T reg selectivity. Comparative analysis revealed that IL2Rα was the optimal cell surface target for T reg selectivity, indicating that avidity for IL2Rα may be the optimal route to producing IL-2 variants that selectively target T regs .